Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomized trial

David Rossini, Alessandro Serretti, Linda Franchini, Laura Mandelli, Enrico Smeraldi, Diana De Ronchi, Raffaella Zanardi

Research output: Contribution to journalArticle

Abstract

Background: Major depression is a common psychiatric disorder in the elderly population. The efficacy of tricyclic antidepressants is well established, and selective serotonin reuptake inhibitors appear to have a similar effectiveness along with advantages in terms of tolerability and safety. Given the lack of literature data regarding fluvoxamine in the treatment of depressed elderly patients, the aim of the present study was to compare its efficacy and tolerability with those of sertraline in a sample of elderly patients. Methods: Under double-blind conditions, 93 hospitalized patients older than 59 years, who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for a major depressive episode, were randomly assigned to receive sertraline (150 mg daily) or fluvoxamine (200 mg daily) for 7 weeks. The clinical response was defined as a reduction on the Hamilton Rating Scale for Depression score to 8 or below. Results: At study completion, the response rates were 55.6% (25/45) and 71.8% (28/39) for sertraline and fluvoxamine, respectively. No significant difference in final response rates was found between the 2 treatment groups (P = 0.12). A repeated-measures analysis of variance on Hamilton Rating Scale for Depression scores revealed a significantly different decrease of depressive symptoms between the 2 treatment groups, favoring fluvoxamine (P = 0.007). The overall safety profile of sertraline and fluvoxamine was favorable with no differences between the 2 drugs. Conclusion: The results of this double-blind trial show that sertraline and fluvoxamine may be effective compounds in the treatment of elderly depression with the latter showing some advantage in terms of speed of response. These findings warrant further replication in placebo-controlled studies.

Original languageEnglish
Pages (from-to)471-475
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume25
Issue number5
DOIs
Publication statusPublished - Oct 2005

Fingerprint

Fluvoxamine
Sertraline
Depression
Therapeutics
Safety
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Double-Blind Method
Diagnostic and Statistical Manual of Mental Disorders
Psychiatry
Analysis of Variance
Placebos
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Sertraline versus fluvoxamine in the treatment of elderly patients with major depression : A double-blind, randomized trial. / Rossini, David; Serretti, Alessandro; Franchini, Linda; Mandelli, Laura; Smeraldi, Enrico; De Ronchi, Diana; Zanardi, Raffaella.

In: Journal of Clinical Psychopharmacology, Vol. 25, No. 5, 10.2005, p. 471-475.

Research output: Contribution to journalArticle

Rossini, David ; Serretti, Alessandro ; Franchini, Linda ; Mandelli, Laura ; Smeraldi, Enrico ; De Ronchi, Diana ; Zanardi, Raffaella. / Sertraline versus fluvoxamine in the treatment of elderly patients with major depression : A double-blind, randomized trial. In: Journal of Clinical Psychopharmacology. 2005 ; Vol. 25, No. 5. pp. 471-475.
@article{f1ef2e5312d34489b841a4623b57c7ca,
title = "Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomized trial",
abstract = "Background: Major depression is a common psychiatric disorder in the elderly population. The efficacy of tricyclic antidepressants is well established, and selective serotonin reuptake inhibitors appear to have a similar effectiveness along with advantages in terms of tolerability and safety. Given the lack of literature data regarding fluvoxamine in the treatment of depressed elderly patients, the aim of the present study was to compare its efficacy and tolerability with those of sertraline in a sample of elderly patients. Methods: Under double-blind conditions, 93 hospitalized patients older than 59 years, who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for a major depressive episode, were randomly assigned to receive sertraline (150 mg daily) or fluvoxamine (200 mg daily) for 7 weeks. The clinical response was defined as a reduction on the Hamilton Rating Scale for Depression score to 8 or below. Results: At study completion, the response rates were 55.6{\%} (25/45) and 71.8{\%} (28/39) for sertraline and fluvoxamine, respectively. No significant difference in final response rates was found between the 2 treatment groups (P = 0.12). A repeated-measures analysis of variance on Hamilton Rating Scale for Depression scores revealed a significantly different decrease of depressive symptoms between the 2 treatment groups, favoring fluvoxamine (P = 0.007). The overall safety profile of sertraline and fluvoxamine was favorable with no differences between the 2 drugs. Conclusion: The results of this double-blind trial show that sertraline and fluvoxamine may be effective compounds in the treatment of elderly depression with the latter showing some advantage in terms of speed of response. These findings warrant further replication in placebo-controlled studies.",
author = "David Rossini and Alessandro Serretti and Linda Franchini and Laura Mandelli and Enrico Smeraldi and {De Ronchi}, Diana and Raffaella Zanardi",
year = "2005",
month = "10",
doi = "10.1097/01.jcp.0000177548.28961.e7",
language = "English",
volume = "25",
pages = "471--475",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Sertraline versus fluvoxamine in the treatment of elderly patients with major depression

T2 - A double-blind, randomized trial

AU - Rossini, David

AU - Serretti, Alessandro

AU - Franchini, Linda

AU - Mandelli, Laura

AU - Smeraldi, Enrico

AU - De Ronchi, Diana

AU - Zanardi, Raffaella

PY - 2005/10

Y1 - 2005/10

N2 - Background: Major depression is a common psychiatric disorder in the elderly population. The efficacy of tricyclic antidepressants is well established, and selective serotonin reuptake inhibitors appear to have a similar effectiveness along with advantages in terms of tolerability and safety. Given the lack of literature data regarding fluvoxamine in the treatment of depressed elderly patients, the aim of the present study was to compare its efficacy and tolerability with those of sertraline in a sample of elderly patients. Methods: Under double-blind conditions, 93 hospitalized patients older than 59 years, who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for a major depressive episode, were randomly assigned to receive sertraline (150 mg daily) or fluvoxamine (200 mg daily) for 7 weeks. The clinical response was defined as a reduction on the Hamilton Rating Scale for Depression score to 8 or below. Results: At study completion, the response rates were 55.6% (25/45) and 71.8% (28/39) for sertraline and fluvoxamine, respectively. No significant difference in final response rates was found between the 2 treatment groups (P = 0.12). A repeated-measures analysis of variance on Hamilton Rating Scale for Depression scores revealed a significantly different decrease of depressive symptoms between the 2 treatment groups, favoring fluvoxamine (P = 0.007). The overall safety profile of sertraline and fluvoxamine was favorable with no differences between the 2 drugs. Conclusion: The results of this double-blind trial show that sertraline and fluvoxamine may be effective compounds in the treatment of elderly depression with the latter showing some advantage in terms of speed of response. These findings warrant further replication in placebo-controlled studies.

AB - Background: Major depression is a common psychiatric disorder in the elderly population. The efficacy of tricyclic antidepressants is well established, and selective serotonin reuptake inhibitors appear to have a similar effectiveness along with advantages in terms of tolerability and safety. Given the lack of literature data regarding fluvoxamine in the treatment of depressed elderly patients, the aim of the present study was to compare its efficacy and tolerability with those of sertraline in a sample of elderly patients. Methods: Under double-blind conditions, 93 hospitalized patients older than 59 years, who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for a major depressive episode, were randomly assigned to receive sertraline (150 mg daily) or fluvoxamine (200 mg daily) for 7 weeks. The clinical response was defined as a reduction on the Hamilton Rating Scale for Depression score to 8 or below. Results: At study completion, the response rates were 55.6% (25/45) and 71.8% (28/39) for sertraline and fluvoxamine, respectively. No significant difference in final response rates was found between the 2 treatment groups (P = 0.12). A repeated-measures analysis of variance on Hamilton Rating Scale for Depression scores revealed a significantly different decrease of depressive symptoms between the 2 treatment groups, favoring fluvoxamine (P = 0.007). The overall safety profile of sertraline and fluvoxamine was favorable with no differences between the 2 drugs. Conclusion: The results of this double-blind trial show that sertraline and fluvoxamine may be effective compounds in the treatment of elderly depression with the latter showing some advantage in terms of speed of response. These findings warrant further replication in placebo-controlled studies.

UR - http://www.scopus.com/inward/record.url?scp=25444532855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444532855&partnerID=8YFLogxK

U2 - 10.1097/01.jcp.0000177548.28961.e7

DO - 10.1097/01.jcp.0000177548.28961.e7

M3 - Article

C2 - 16160624

AN - SCOPUS:25444532855

VL - 25

SP - 471

EP - 475

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -